Senior Manager / Associate Director, HCP NPP Omnichannel Marketing

Bothell, WA (On-site)

$190K/yr – $230K/yrSenior Level5+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive and manage data-driven HCP omnichannel campaigns with AI-enabled targeting across oncology, coordinating field, digital, and non-personal channels.

  • Must-have: 5+ years in pharma/healthcare marketing with digital and omnichannel expertise plus oncology launch experience.
  • Standout: Strong MLR/PRC, OPDP compliance, and agency/budget management.
  • Standout: AI-ready with predictive analytics and next-best-action capabilities.

Job Description

Responsibilities

  • Develop and execute data-driven HCP digital campaigns, content, and modular journeys based on time to diagnosis, specialty, prescribing behavior, and real-time engagement signals to drive disease education and product adoption
  • Manage marketing automation platforms and digital engagement tools to enable personalized HCP communication
  • Monitor and analyze campaign performance and engagement metrics to continuously refine targeting, creative assets, and channel mix
  • Partner with media agencies to develop and optimize channel strategy, media planning and activation, ensuring precise audience targeting and efficient budget allocation
  • Lead the development and execution of the HCP non-personal promotion and omnichannel engagement strategy
  • Design customer journeys that coordinate field promotion, digital engagement, and non-personal channels to deliver a cohesive HCP experience
  • Design and implement an integrated digital ecosystem (e.g., websites, search, social, CRM, programmatic media, and paid search) that supports education, activation, and sustained engagement
  • Champion the adoption of AI-driven marketing capabilities, including predictive analytics, machine learning models, and automated decisioning engines to enhance targeting, personalization, and campaign performance
  • Leverage AI and advanced analytics to enable next-best-action/next-best-message frameworks, dynamic content personalization, and real-time optimization of HCP engagement
  • Partner with analytics and technology teams to pilot and scale new AI-enabled marketing solutions while ensuring compliance with regulatory and data governance standards

Requirements

  • Bachelor’s degree required; Advanced degree (e.g., PharmD, MBA) preferred
  • 5+ years of experience in pharmaceutical, biotech, or healthcare marketing, with a strong focus on digital, NPP, and omnichannel strategy
  • Oncology launch experience required
  • Proven success in digital HCP marketing (web, social, SEO/SEM, CRM, and paid media strategy) and in media planning and execution
  • Strong understanding of MLR/PRC processes, claims substantiation, and OPDP regulations
  • Demonstrated ability to thrive in a fast-paced biotech environment
  • Ability to travel ≥20%, including occasional weekends
  • HCP digital and NPP expertise: Deep understanding of HCP digital engagement tactics and how to integrate channels into cohesive omnichannel journeys
  • Strong analytical and problem-solving skills, with the ability to leverage market research and performance data to inform decisions and optimize impact
  • Strong project management and operational execution skills; able to manage multiple workstreams and launch-critical deadlines in a fast-paced environment
    Immunome, Inc. logo

    Immunome, Inc.

    2.5 Glassdoor

    Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

    Founded in 2008
    Bothell, Washington, USA
    187 employees (3 in marketing)
    58% recommend to a friend

    Traffic Signals

    Monthly Visitors
    12.4K
    Traffic Source Mix
    Search
    31.1%
    Direct
    45.6%
    Referral
    6.5%
    Social
    15.2%
    Paid
    1.5%

    Headcount Trend

    Current headcount: ~191

    Marketing Team

    Marketing Team Size
    3 (2% of company)

    Funding

    Total Funding
    $998.9M
    Last Raise
    $400M
    Post IPO Equity, 3 months ago

    Funding History

    • Dec 2025
      Post IPO Equity • $400M
    • Jan 2025
      Post IPO Equity • $150M
    • Feb 2024
      Post IPO Equity • $230M

    Recent News